ECSP11011155A - DERIVADOS DE 2-PIRIDIN-2-IL-PIRAZOL-3(2H)-ONA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA COMO ACTIVADORES de HIF - Google Patents
DERIVADOS DE 2-PIRIDIN-2-IL-PIRAZOL-3(2H)-ONA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA COMO ACTIVADORES de HIFInfo
- Publication number
- ECSP11011155A ECSP11011155A EC2011011155A ECSP11011155A ECSP11011155A EC SP11011155 A ECSP11011155 A EC SP11011155A EC 2011011155 A EC2011011155 A EC 2011011155A EC SP11011155 A ECSP11011155 A EC SP11011155A EC SP11011155 A ECSP11011155 A EC SP11011155A
- Authority
- EC
- Ecuador
- Prior art keywords
- group
- alkyl
- aryl
- heterocycloalkyl
- hydrogen atom
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000012190 activator Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
Abstract
La invención se refiere a los compuestos que responden a la fórmula (I) : R representa un grupo -SO2-NR3R4, un átomo de hidrógeno, un átomo de halógeno, un grupo -halógenoalquilo(C1-C5), un grupo -CO2R5 o un grupo -SO2-R4 ; R1 representa un grupo heterocicloalquilo que no contiene átomo de nitrógeno, un grupo-W-cicloalquilo(C3-C6), un grupo -W-arilo, un grupo -W-heteroarilo, un grupo -W-heterocicloalquilo, un grupo -W-COOR5, un grupo -W-CONR5R6 ; R2 representa un átomo de hidrógeno, un grupo -alquilo(C1-C5), un grupo -alquileno(C1-C5)-O-alquilo(C1-C5), un grupo -halógenoalquilo(C1-C5), un grupo -W-COOR5, un grupo -W-C(O)NHR5 o un grupo -W-C(O)-NR5R6 ; n representa 0, 1 ó 2 ; W es un grupo -alquileno(C1-C5)- o un grupo -cicloalquileno(C3-C6)- ; R3 y R4, idénticos o diferentes, representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo -alquilo(C1-C5), un grupo -cicloalquilo(C3-C6), un grupo -alquileno(C1-C5)-O-alquilo(C1-C5), un arilo, un grupo -CH2-arilo, un heteroarilo, un heterocicloalquilo, un grupo -W-OH, un grupo -W-CHOH-CH2OH, un grupo -W-CO2R5, un grupo -W-NR5R6 o un grupo -W-O-(CH2)n-arilo; o bien R3 y R4 forman junto con el átomo de nitrógeno al que están unidos un grupo heterocicloalquilo ; R5 y R6, idénticos o diferentes, representan, independientemente el uno del otro, un átomo de hidrógeno, un grupo -alquilo(C1-C5) o un grupo halógenoalquilo(C1-C5), así como su procedimiento de preparación y sus aplicaciones en terapéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0807474A FR2940651B1 (fr) | 2008-12-29 | 2008-12-29 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique comme activateurs de hif |
| FR0904092A FR2949466A1 (fr) | 2009-08-28 | 2009-08-28 | Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011155A true ECSP11011155A (es) | 2011-07-29 |
Family
ID=42008610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011155A ECSP11011155A (es) | 2008-12-29 | 2011-06-22 | DERIVADOS DE 2-PIRIDIN-2-IL-PIRAZOL-3(2H)-ONA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA COMO ACTIVADORES de HIF |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US8541455B2 (es) |
| EP (1) | EP2382205B1 (es) |
| JP (1) | JP5734870B2 (es) |
| KR (1) | KR20110099786A (es) |
| CN (1) | CN102333769B (es) |
| AR (1) | AR074915A1 (es) |
| AU (1) | AU2009334569B2 (es) |
| BR (1) | BRPI0924060A8 (es) |
| CA (1) | CA2748411A1 (es) |
| CL (1) | CL2011001496A1 (es) |
| CO (1) | CO6400141A2 (es) |
| CR (1) | CR20110361A (es) |
| CY (1) | CY1115368T1 (es) |
| DK (1) | DK2382205T3 (es) |
| EA (1) | EA019591B1 (es) |
| EC (1) | ECSP11011155A (es) |
| ES (1) | ES2481042T3 (es) |
| HR (1) | HRP20140680T1 (es) |
| IL (1) | IL213789A (es) |
| MA (1) | MA32976B1 (es) |
| MX (1) | MX2011007054A (es) |
| MY (1) | MY179093A (es) |
| NZ (1) | NZ593751A (es) |
| PA (1) | PA8856201A1 (es) |
| PE (1) | PE20120416A1 (es) |
| PL (1) | PL2382205T3 (es) |
| PT (1) | PT2382205E (es) |
| SG (1) | SG172803A1 (es) |
| SI (1) | SI2382205T1 (es) |
| SM (1) | SMT201400097B (es) |
| TN (1) | TN2011000267A1 (es) |
| TW (1) | TWI482763B (es) |
| UY (1) | UY32369A (es) |
| WO (1) | WO2010076524A2 (es) |
| ZA (1) | ZA201104783B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101630475B1 (ko) | 2008-12-29 | 2016-06-14 | 사노피 | ２-피리딘-２-일-피라졸-３（２ｈ）-온의 유도체, 그의 제조법 및 치료 용도 |
| JP5902671B2 (ja) * | 2011-03-31 | 2016-04-13 | キッセイ薬品工業株式会社 | ベンジルピラゾール誘導体の製造方法およびその製造中間体 |
| IN2014MN01988A (es) * | 2012-03-30 | 2015-07-10 | Daiichi Sankyo Companyltd | |
| PT2978752T (pt) * | 2013-03-29 | 2018-03-09 | Takeda Pharmaceuticals Co | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e o seu uso como inibidores de phd |
| DE102016223133A1 (de) | 2016-11-23 | 2018-05-24 | Deere & Company | Geschwindigkeitskontrolle einer Erntemaschine |
| CA3176142A1 (en) * | 2020-03-20 | 2021-09-23 | Akebia Therapeutics, Inc. | Phd inhibitor compounds, compositions, and use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4023488A1 (de) * | 1990-07-24 | 1992-01-30 | Bayer Ag | 1-(pyri(mi)dyl-(2)) -5-hydroxy-pyrazol-mikrobizide |
| US5750088A (en) | 1993-03-30 | 1998-05-12 | The Dupont Merck Pharmaceutical Company | Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals |
| CA2530679A1 (en) | 2003-06-30 | 2005-04-07 | Hif Bio, Inc. | Compounds for treating angiogenesis |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| PE20071020A1 (es) | 2006-03-07 | 2007-12-11 | Smithkline Beecham Corp | Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa |
| WO2008047198A1 (en) | 2006-10-16 | 2008-04-24 | Pfizer Products Inc. | Therapeutic pyrazolyl thienopyridines |
| DE102006050516A1 (de) | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dihydropyrazolone und ihre Verwendung |
| JP5702138B2 (ja) | 2007-05-18 | 2015-04-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 過剰増殖障害および血管新生に関連する疾患の処置に有用なヘテロアリール置換ピラゾール誘導体 |
-
2009
- 2009-12-24 BR BRPI0924060A patent/BRPI0924060A8/pt not_active IP Right Cessation
- 2009-12-24 WO PCT/FR2009/052691 patent/WO2010076524A2/fr not_active Ceased
- 2009-12-24 CN CN200980157590.6A patent/CN102333769B/zh not_active Expired - Fee Related
- 2009-12-24 JP JP2011542886A patent/JP5734870B2/ja not_active Expired - Fee Related
- 2009-12-24 PE PE2011001292A patent/PE20120416A1/es not_active Application Discontinuation
- 2009-12-24 PL PL09805789T patent/PL2382205T3/pl unknown
- 2009-12-24 DK DK09805789.6T patent/DK2382205T3/da active
- 2009-12-24 HR HRP20140680AT patent/HRP20140680T1/hr unknown
- 2009-12-24 AU AU2009334569A patent/AU2009334569B2/en not_active Ceased
- 2009-12-24 CA CA2748411A patent/CA2748411A1/fr not_active Abandoned
- 2009-12-24 ES ES09805789.6T patent/ES2481042T3/es active Active
- 2009-12-24 SI SI200930983T patent/SI2382205T1/sl unknown
- 2009-12-24 NZ NZ593751A patent/NZ593751A/xx not_active IP Right Cessation
- 2009-12-24 MA MA34027A patent/MA32976B1/fr unknown
- 2009-12-24 EP EP09805789.6A patent/EP2382205B1/fr active Active
- 2009-12-24 KR KR1020117017676A patent/KR20110099786A/ko not_active Abandoned
- 2009-12-24 MY MYPI2011003012A patent/MY179093A/en unknown
- 2009-12-24 EA EA201170899A patent/EA019591B1/ru not_active IP Right Cessation
- 2009-12-24 PT PT98057896T patent/PT2382205E/pt unknown
- 2009-12-24 SG SG2011047503A patent/SG172803A1/en unknown
- 2009-12-24 MX MX2011007054A patent/MX2011007054A/es active IP Right Grant
- 2009-12-28 TW TW098145336A patent/TWI482763B/zh not_active IP Right Cessation
- 2009-12-28 AR ARP090105126A patent/AR074915A1/es unknown
- 2009-12-29 UY UY0001032369A patent/UY32369A/es not_active Application Discontinuation
- 2009-12-29 PA PA20098856201A patent/PA8856201A1/es unknown
-
2011
- 2011-05-24 TN TN2011000267A patent/TN2011000267A1/fr unknown
- 2011-06-17 CL CL2011001496A patent/CL2011001496A1/es unknown
- 2011-06-22 EC EC2011011155A patent/ECSP11011155A/es unknown
- 2011-06-23 CR CR20110361A patent/CR20110361A/es unknown
- 2011-06-27 IL IL213789A patent/IL213789A/en not_active IP Right Cessation
- 2011-06-28 ZA ZA2011/04783A patent/ZA201104783B/en unknown
- 2011-06-29 CO CO11081326A patent/CO6400141A2/es active IP Right Grant
- 2011-06-29 US US13/172,305 patent/US8541455B2/en not_active Expired - Fee Related
-
2014
- 2014-07-22 SM SM201400097T patent/SMT201400097B/xx unknown
- 2014-07-23 CY CY20141100553T patent/CY1115368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011155A (es) | DERIVADOS DE 2-PIRIDIN-2-IL-PIRAZOL-3(2H)-ONA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA COMO ACTIVADORES de HIF | |
| CO6290657A2 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-alfa]piridinas su preparacion y su aplicacion en terapeutica | |
| ECSP11010912A (es) | Compuestos de pirrol | |
| CU23926B1 (es) | Derivado de oxopirazina y herbicida | |
| AR049784A1 (es) | Derivados sustituidos de morfolina y tiomorfolina | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR080314A1 (es) | Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa | |
| CR10643A (es) | DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZOL[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA | |
| CO6210751A2 (es) | Derivados de indolinona y procedimiento para su fabricacion | |
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| MX2010002272A (es) | 4-(4-piridinil)-benzamidas y su uso como moduladores de la actividad de rho-cinasa (rock). | |
| AR082788A1 (es) | Composiciones pesticidas y procesos de preparacion de los mismos | |
| EA200970493A1 (ru) | Макроциклические ингибиторы вируса гепатита с | |
| CO6150147A2 (es) | Derivados de 5,6-bisaril-2-piridin-carboxamida su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| AR099913A1 (es) | Derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR049543A1 (es) | Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica | |
| AR077363A1 (es) | DERIVADOS DE 1,2,3,4- TETRAHIDRO-PIRIMIDO{1,2-A} PIRIMIDIN-6-ONA, SU PREPARACIoN, SU UTILIZACIoN EN QUIMIOTERAPIA Y SUS COMPOSICIONES FARMACEUTICAS. | |
| BR112012025820A2 (pt) | método de analisar uma célula ou outro material biológico compreendendo um ácido nucleico | |
| AR087494A1 (es) | Derivados de isoxazolina como compuestos insecticidas | |
| CO6320143A1 (es) | Nuevos derivados dihidroindolonas su procedimeinto de preparacion y composiciones farmaceuticas que los contienen | |
| CO6480974A2 (es) | Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt(pkb) | |
| BR112017019439A2 (pt) | inibidores kv1.3 e sua aplicação médica | |
| AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
| CO6400145A2 (es) | Derivados de 2-piridin-2-il pirazol-3(2h) -ona, su preparción y su aplicación terapeútica | |
| BR112021026899A2 (pt) | Compostos heterocíclicos |